Skip to content
Homepage
Author:
Taysha Gene Therapies, Inc.
Posted Date:
June 25, 2026
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Taysha Gene Therapies, Inc.
June 25, 2026
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies, Inc.
June 24, 2026
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies, Inc.
June 24, 2026
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
Taysha Gene Therapies, Inc.
June 22, 2026
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc.
June 5, 2026
